{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:48:54Z","timestamp":1789408134802,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Humedics GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are recommended to treat patients with early or intermediate hepatocellular carcinoma (HCC). The liver maximum capacity test (LiMAx) has been supposed to predict the risk of post-interventional liver failure. We investigated the correlation of LiMAx with short-term survival as primary endpoint and the occurrence of adverse events after therapy as secondary endpoint. Our study cohort prospectively included 69 patients receiving TACE (n = 57) or TARE (n = 12). LiMAx test and serological analyses were performed on the day before and 4 weeks after treatment. Hepatic and extrahepatic complications were monitored for 4 weeks. The LiMAx results were not associated with altered liver function and the occurrence of adverse events. The survival rates of patients with BCLC A with LiMAx \u2264 150 \u03bcg\/kg\/h were lower after 30 days (75.0 \u00b1 15.3% vs. 100%, p = 0.011), 90 days (62.5 \u00b1 17.7% vs. 95.8 \u00b1 4.1%, p = 0.011) and 180 days (50.0 \u00b1 17.7% vs. 95.8 \u00b1 4.1%, p = 0.001) compared to those with higher LiMAx levels. The LiMAx test is not suitable to predict liver function abnormalities or the occurrence of complications 4 weeks after therapy but enables the identification of patients with early stage HCC and reduced short-term survival after treatment.<\/jats:p>","DOI":"10.3390\/cancers14215323","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:45:00Z","timestamp":1667087100000},"page":"5323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-101X","authenticated-orcid":false,"given":"Janett","family":"Fischer","sequence":"first","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Wellh\u00f6ner","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ebel","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lincke","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"B\u00f6hlig","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gerhardt","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Veelken","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Goessmann","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7598-0758","authenticated-orcid":false,"given":"Karen Geva","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3208","authenticated-orcid":false,"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-6241","authenticated-orcid":false,"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0672","authenticated-orcid":false,"given":"Florian van","family":"B\u00f6mmel","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global Cancer Statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12029-017-9973-2","article-title":"HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)","volume":"48","year":"2017","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7861\/clinmedicine.17-5-449","article-title":"Selective internal radiation therapy for liver tumours","volume":"17","author":"Sundram","year":"2017","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chang, Y., Jeong, S.W., Jang, J.Y., and Kim, Y.J. (2020). Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218165"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13645706.2018.1432489","article-title":"Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments","volume":"27","author":"Gnutzmann","year":"2018","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kishore, S.A., Bajwa, R., and Madoff, D.C. (2020). Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers, 12.","DOI":"10.3390\/cancers12040791"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000485471","article-title":"Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit\/Risk Assessment","volume":"7","author":"Piscaglia","year":"2018","journal-title":"Liver Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.aidm.2013.12.001","article-title":"Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization","volume":"1","author":"Lin","year":"2014","journal-title":"Adv. Dig. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3748\/wjg.v21.i21.6518","article-title":"Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives","volume":"21","author":"Sacco","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy","volume":"28","author":"Gaba","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Demirtas, C.O., D\u2019Alessio, A., Rimassa, L., Sharma, R., and Pinato, D.J. (2021). ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep., 3.","DOI":"10.1016\/j.jhepr.2021.100347"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3350\/cmh.2020.0204","article-title":"Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects","volume":"27","author":"Torimura","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/JHC.S285735","article-title":"Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide","volume":"8","author":"Stoehr","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4103\/jcrt.JCRT_52_19","article-title":"Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application","volume":"15","author":"Wei","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kohla, M.A.S., Abu Zeid, M.I., Al-Warraky, M., Taha, H., and Gish, R.G. (2015). Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol., 2.","DOI":"10.1136\/bmjgast-2015-000032"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","article-title":"Updated treatment approach to hepatocellular carcinoma","volume":"40","author":"Llovet","year":"2005","journal-title":"J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/COC.0000000000000384","article-title":"Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated with Radioembolization","volume":"41","author":"Gui","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/jso.24992","article-title":"ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma","volume":"117","author":"Na","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lescure, C., Estrade, F., Pedrono, M., Campillo-Gimenez, B., Le Sourd, S., Pracht, M., Palard, X., Bourien, H., Muzellec, L., and Uguen, T. (2021). ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153794"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.diii.2019.05.006","article-title":"Intra-arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization","volume":"100","author":"Delicque","year":"2019","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Buechter, M., Kersting, S., Gerken, G., and Kahraman, A. (2019). Enzymatic liver function measured by LiMAx\u2013a reliable diagnostic and prognostic tool in chronic liver disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49746-1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10620-018-5360-5","article-title":"Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis","volume":"64","author":"Jara","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1665-2681(19)31339-0","article-title":"Predicting the prognosis in acute liver failure: Results from a retrospective pilot study using the LiMAx test","volume":"12","author":"Lock","year":"2013","journal-title":"Ann. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000503098","article-title":"Predictive Power of Liver Maximum Function Capacity Test in Transjugular Intrahepatic Portosystemic Shunt Patients: A Pilot Study","volume":"38","author":"Reichert","year":"2020","journal-title":"Dig. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kaffarnik, M.F., Lock, J.F., Vetter, H., Ahmadi, N., Lojewski, C., Malinowski, M., Neuhaus, P., and Stockmann, M. (2013). Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: A prospective study with the LiMAx test. Crit. Care, 17.","DOI":"10.1186\/cc13089"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1477-2574.2009.00151.x","article-title":"The LiMAx test: A new liver function test for predicting postoperative outcome in liver surgery","volume":"12","author":"Stockmann","year":"2010","journal-title":"HPB"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","article-title":"Prediction of Postoperative Outcome After Hepatectomy With a New Bedside Test for Maximal Liver Function Capacity","volume":"250","author":"Stockmann","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/tri.12441","article-title":"Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: A prospective study with the LiMAx test","volume":"28","author":"Jara","year":"2015","journal-title":"Transpl. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s10620-020-06535-5","article-title":"Volume\u2013Function Analysis (LiMAx Test) in Patients with HCC and Cirrhosis Undergoing TACE\u2014A Feasibility Study","volume":"66","author":"Reichert","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00270-019-02325-3","article-title":"Monitoring Liver Function of Patients Undergoing Transarterial Chemoembolization (TACE) by a 13C Breath Test (LiMAx)","volume":"42","author":"Barzakova","year":"2019","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/CH-219118","article-title":"Prediction of transarterial chemoembolization (TACE) outcome by pre- and postinterventional 13C-methacetin breath test","volume":"79","author":"Senk","year":"2021","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, J., and Jung, Y. (2017). Radiation-induced liver disease: Current understanding and future perspectives. Exp. Mol. Med., 49.","DOI":"10.1038\/emm.2017.85"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jss.2014.07.041","article-title":"Reliable assessment of liver function using LiMAx","volume":"193","author":"Jara","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_37","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl. Clin. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath","year":"2007","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Van Thai, N., Thinh, N.T., Ky, T.D., Bang, M.H., Giang, D.T., Le Ha, N., Son, M.H., Tien, D.D., and Lee, H.W. (2021). Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01805-6"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cld.2015.01.008","article-title":"Locoregional Therapy of Hepatocellular Carcinoma","volume":"19","author":"Habib","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.seminoncol.2012.05.004","article-title":"Chemoembolization for Hepatocellular Carcinoma","volume":"39","author":"Lencioni","year":"2012","journal-title":"Semin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4254\/wjh.v7.i1.40","article-title":"Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma","volume":"7","author":"Gao","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_45","first-page":"25","article-title":"Interventional Radiologic Treatment of Hepatocellular Carcinoma","volume":"15","author":"Boyvat","year":"2017","journal-title":"Exp. Clin. Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:26Z","timestamp":1760144726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":45,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14215323"],"URL":"https:\/\/doi.org\/10.3390\/cancers14215323","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}